VIADERM KC Cream, Ointment (2022)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
1. Name of the medicinal product
Viaderm KC Cream & Ointment.
2. Qualitative and quantitative composition
Cream: 1 gram contains the following active ingredients: 0.025% gramicidin 0.25% neomycin 100 000U nystatin 0.1% triamcinolone acetonide Ointment: 1 gram contains the following active ingredients: 0.025% ...
3. Pharmaceutical form
Topical cream and topical ointment.
4.1. Therapeutic indications
The topical treatment of superficial bacterial infections, cutaneous candidosis and dermatological conditions known to respond to topical steroid therapy when threatened or complicated by bacterial or ...
4.2. Posology and method of administration
Adults and Children Apply to the affected areas two to four times daily. Rebound of pre-existing dermatoses can occur with abrupt discontinuation of topical corticosteroid preparations. Elderly Natural ...
4.3. Contraindications
In tuberculosis and most viral lesions of the skin, particularly herpes simplex, vaccinia and varicella. Also, in fungal lesions not susceptible to nystatin. In patients with hypersensitivity to any of ...
4.4. Special warnings and precautions for use
Adrenal suppression can occur, even without occlusion. The use of occlusive dressings should be avoided because of the increased risk of sensitivity reactions and increased percutaneous absorption. The ...
4.5. Interaction with other medicinal products and other forms of interaction
No data available.
4.6. Fertility, pregnancy and lactation
Pregnancy Topical administration of corticosteroids to pregnant animals can cause abnormalities of foetal development. The relevance of this finding to humans has not been established. However, topical ...
4.7. Effects on ability to drive and use machines
Not applicable.
4.8. Undesirable effects
General disorders and administration site conditions Rebound effect – see Section 4.2 Dose and method of administration. <u>Triamcinolone acetonide</u> is well tolerated. Where adverse reactions occur, ...
4.9. Overdose
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 ...
5.1. Pharmacodynamic properties
Triamcinolone acetonide is a potent fluorinated corticosteroid with rapid anti-inflammatory action, anti-pruritic and anti-allergic actions. The combined action of the antibiotics neomycin and gramicidin ...
5.2. Pharmacokinetic properties
Absorption The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressing. ...
5.3. Preclinical safety data
No data available.
6.1. List of excipients
Cetomacrogol Citric acid monohydrate Dibasic sodium phosphate monohydrate Ethanol Liquid paraffin Methyl hydroxybenzoate Perfume 5254 Propyl hydroxybenzoate Propylene glycol Purified water White soft paraffin ...
6.2. Incompatibilities
Not applicable.
6.3. Shelf life
24 months.
6.4. Special precautions for storage
Store below 25°C.
6.5. Nature and contents of container
15 g tubes.
6.6. Special precautions for disposal and other handling
No special precautions.
7. Marketing authorization holder
AFT Pharmaceuticals Ltd, Level 1, 129 Hurstmere Road, Takapuna, Auckland, 0622, New Zealand
9. Date of first authorization / renewal of the authorization
16 May 2002
10. Date of revision of the text
28 March 2022
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
